Dr. Braddock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
310 CEDAR STREET
BML-165
New Haven, CT 06510Phone+1 203-737-1278
Summary
- I am a physician/scientist, at Yale, where I have led an independently funded laboratory and practiced hematopathology since 2004. My laboratory's focus is the study severe poorly addressed human disease with an emphasis on the elucidation of disease pathogenesis to unveil therapeutic targets. I am particularly interested in rare diseases of children, and in the design and engineering of novel biologics to modulate disease outcome.
Education & Training
- National Institutes of Health Clinical CenterResidency, Pathology-Anatomic and Clinical, 1996 - 2000
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1996
- University of ChicagoPh.D., Biochemistry, 1994
- University of ChicagoA.B., Chemistry, 1988
Certifications & Licensure
- TN State Medical License 2012 - 2026
- CT State Medical License 2004 - 2025
- NY State Medical License 2012 - 2025
- CA State Medical License 2010 - 2023
- MD State Medical License 2012 - 2022
- NJ State Medical License 2012 - 2021
- GA State Medical License 2012 - 2020
- American Board of Pathology Anatomic Pathology
- American Board of Pathology Hematopathology
- Join now to see all
Awards, Honors, & Recognition
- Commissioned Officer U.S. Public Health Service Home (USPHS)
- Dean's List University of Chicago
- Emerging Leaders' Program Yale New Haven Hospital (YNHH), Yale School of Management, 2014
- Join now to see all
Publications & Presentations
PubMed
- 870 citationsMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenaseAnila K. Madiraju, Derek M. Erion, Yasmeen Rahimi, Xian-Man Zhang, Demetrios T. Braddock
Nature. 2014-06-26 - 607 citationsMicroRNA silencing for cancer therapy targeted to the tumour microenvironmentChristopher J. Cheng, Raman Bahal, Imran A. Babar, Zachary Pincus, Francisco N. Barrera
Nature. 2015-02-05 - 33 citationsClinical and Biochemical Phenotypes in a Family With ENPP1 MutationsAnupam Kotwal, Alejandro Ferrer, Rajiv Kumar, Ravinder J. Singh, Vishakantha Murthy
Journal of Bone and Mineral Research. 2020-04-01
Journal Articles
- "In vivo correction of anaemia in Beta-thalassemic mice by gammaPNA-mediated gene editing with nanoparticle delivery"Bahal R, Ali McNeer N, Quijano E, Liu Y, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, Lopez-Giraldez F, Ricciardi A, Beloor J, K..., Nature Communications, 1/26/2016
- "pHLIP® targeting of PNA to silence MicroRNA in tumors"Cheng, C.J., Bahal, R., Babar, I.A., Pincus, Z., Barrera, F., Liu, C., Svoronos, A., Braddock, D.T., Glazer, P.M., Engelman, D.M., Saltzman, W.M., Slack, F.J., Nature, 1/5/2015
- "ENPP1-Fc Fusion Protein Prevents Mortality and Vascular Calcifications in Rodent Model of Generalized Calcification of Infancy"Albright, R.A., Stabach, P., Cao, W., Kavanagh, D., Mullen, I., Braddock, A.A., Covo M.S., Tehan, M., Yang, G., Cheng, Z., Bouchard, K., Zhao-Xue, Y., Thorn, S., Wang,..., Nature Communications, 1/1/2015
- Join now to see all
Books/Book Chapters
Press Mentions
- Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business UpdatesAugust 15th, 2022
- Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business HighlightsMay 10th, 2022
- Faculty Entrepreneurs Receive Research Support from Blavatnik Fund for Innovation at YaleMay 21st, 2021
- Join now to see all
Grant Support
- ENPP1 regulation of mammalian bone massNIH/NIAMS2022–2027
- Targeting NETs in Human DiseaseBlavatnik Foundation2021–2023
- Enzyme Therapy for CKD-MDB: Breaking the Barrier of Vascular CalcificationNIH/NIDDK2020–2023
- Discovery, Validation, and Translational Development of Biologic Therapeutics for Ectopic Calcification DisordersInozyme Pharma2017–2023
- Non – Nuclease Based Gene Editing for Hutchinson-Gilford ProgeriaNIH/NIAID2020–2022
- Structure-Function Studies On PUF60 &On Npp4National Center For Research Resources2011
- Locating The Regions Of An Adml 3'Intron RNA Analogue Bound To PUF60 RrmsNational Center For Research Resources2011
- Structure Of The Prometastatic Enzyme AutotaxinNational Center For Research Resources2010
- 3D Determination Of An Npase PhosphodiesteraseNational Center For Research Resources2008–2010
- Fir:Fuse ComplexNational Center For Research Resources2006
Industry Relationships
- Founder, SAB member, and Consultant, Inozyme Phama2017 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: